Myasthenia Gravis Therapeutics Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

Global Myasthenia Gravis Therapeutics Market Trends and Insights

Rising incidence & earlier diagnosis

Incidence rose to 68.5 new U.S. cases per million in 2024, reflecting growing awareness and improved insurance coverage for neuromuscular testing. In tertiary clinics, AI-assisted ocular-motor analytics can identify fatigue signatures in under 60 seconds and have been associated with reducing average diagnostic lag from 2.3 years to under 12 months.^{[1]Yun Ye, “Epidemiology of myasthenia gravis in the United States,” Frontiers in Neurology, frontiersin.org} Early confirmation allows clinicians to initiate immune-modifying therapy sooner, and centers that achieve a sub-one-year diagnosis report 40% higher minimal manifestation rates at two-year follow-up. Broader tele-neurology access, coupled with payer incentives for prompt work-ups, continues to enlarge the myasthenia gravis therapeutics market patient pool.

Accelerated approvals of FcRn/complement biologics

Between 2023 and 2025, four breakthrough drugs—rozanolixizumab, zilucoplan, nipocalimab and SC efgartigimod—completed regulatory review in just 6-8 months under priority pathways. Condensed timelines shorten cash-burn periods, encouraging venture investors and fostering big-pharma deal activity. Parallel approvals in the EU, Japan and Australia allow near-simultaneous launches, accelerating global revenue capture during exclusivity windows. These dynamics add scale and depth to the myasthenia gravis therapeutics market and validate precision immunology as a core growth theme.

Rare-disease incentives & premium pricing

Orphan-drug status grants seven-year exclusivity, a 25% R&D tax credit and waived FDA user fees, removing sizable regulatory costs. List prices exceed USD 800,000 per patient-year, yet outcomes-based contracts mitigate payer pushback while preserving strong net revenue flows. Manufacturers channel high margins into next-generation programs such as CAART and bispecific antibodies, reinforcing a virtuous investment cycle that keeps the myasthenia gravis therapeutics industry attractive for both incumbents and entrants.

SC biologics improving adherence

EMA clearance for self-injected rozanolixizumab and FDA approval of Vyvgart Hytrulo prefilled syringes shift treatment from infusion suites to the home, raising adherence from 65% to 89% within six months of rollout. Home dosing eliminates travel burdens, an advantage cited by 83% of survey respondents. Improved persistence yields steadier IgG suppression, fewer exacerbations and lower crisis-related hospitalizations, strengthening the clinical and economic rationale for biologic use in the myasthenia gravis therapeutics market.

High biologic therapy cost

Annual FcRn inhibitor expenditure approximates USD 833,000, while cost-utility studies suggest prices must fall by up to 88% to meet willingness-to-pay thresholds in the United States and Europe.^{[2] Young-Ah Heo, “Efgartigimod: A Review in Generalized Myasthenia Gravis,” Journal of Managed Care & Specialty Pharmacy, jmcp.org} Budget caps trigger prior-authorization delays of four to six weeks, and emerging-market patients often default to steroids or plasmapheresis because of high co-payments. Wide affordability gaps therefore temper demand growth for the myasthenia gravis therapeutics market despite clinical superiority of novel agents.

Low disease awareness in emerging economies

Primary-care recognition of myasthenia gravis averages below 30% in many APAC and Latin American settings, with misdiagnosis at initial presentation exceeding 60%.^{[3]Yasar Zorlu, “Decoding myasthenia gravis with infrared spectroscopy,” Scientific Reports, nature.com} Patients may rotate through ophthalmology and ENT services for up to a year before being referred to neurology, potentially delaying access to disease-modifying therapy. These factors restrict market penetration, keeping prescription volumes low even when products receive regulatory approval.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Segment Analysis

By Treatment: Gene Therapies Accelerate Precision Care

Gene and cell therapies are the fastest-growing treatment category at a 9.41% CAGR, though medication regimens still captured 68.74% of 2025 revenue. Early CAR-T case studies show Quantitative MG scores dropping from 21 to 5, sustaining muscle strength gains without ongoing immunosuppression. Telitacicept’s 98.1% MG-ADL response in late-stage trials and CAART technology that selectively depletes pathogenic B cells reinforce growing confidence in curative approaches. Venture capital and disease-foundation grants provide critical funding, while regulators familiar with AAV vectors streamline IND reviews. As one-time interventions mature, the myasthenia gravis therapeutics market may shift toward front-loaded revenue, with chronic medication budgets gradually pivoting to post-treatment monitoring.

The existing medication segment remains sizeable because steroids, cholinesterase inhibitors and IVIg continue to manage mild or rapidly progressive episodes. Nonetheless, FcRn antagonists and complement inhibitors now enable steroid tapering in nearly half of patients, eroding dependence on broad immunosuppressants. Combination protocols blending biologics with targeted gene-editing may create hybrid models of care that preserve maintenance margins while unlocking durable remission for high-risk groups. Such innovation sustains revenue diversity in the myasthenia gravis therapeutics market and cushions drug makers against binary regulatory outcomes.

By Route of Administration: SC Delivery Redefines Convenience

Subcutaneous administration is growing 9.85% annually and is poised to chip away at intravenous dominance, which accounted for 62.90% of revenue in 2025. EMA endorsement of self-injected rozanolixizumab and FDA clearance for Vyvgart Hytrulo prefilled syringes confirm the safety and efficacy of patient-controlled delivery. SC dosing can be completed in five minutes at home, compared with several-hour infusion visits, lifting adherence to 89% and driving switch-over among patients eager to reduce clinic time. Such convenience broadens the myasthenia gravis therapeutics market size by engaging rural residents and mobility-limited patients who previously skipped biologic therapy.

Technology partnerships, like argenx’s USD 30 million expansion with Halozyme, target higher drug concentrations and smaller injection volumes, enhancing comfort and logistics. The shift frees infusion chairs for other specialties, a benefit valued by hospital administrators, and lowers payer facility costs. Oral formulations remain confined to legacy cholinesterase inhibitors and steroids, yet future extended-release or nanoparticle biologics could move additional therapies into home care. Broader SC penetration will therefore continue reshaping revenue allocation within the myasthenia gravis therapeutics market.

By Drug Class: Monoclonal Antibodies Outpace Legacy Drugs

Monoclonal antibodies posted the highest growth trajectory at an 11.06% CAGR through 2031, although cholinesterase inhibitors still generated 45.98% of 2025 revenue. FcRn antagonists such as efgartigimod, rozanolixizumab and nipocalimab deliver rapid IgG reduction, improving MG-ADL and QMG scores within weeks. Complement inhibitors remain critical for patients with complement-mediated pathology, offering remission prospects when autoantibody titers stay elevated despite FcRn therapy. Rituximab retains a niche in MuSK-positive disease, with 97% of recipients achieving improved clinical status yet limited by off-label reimbursement hurdles.

Pipeline diversification includes C2 inhibitors and MuSK agonists, suggesting fresh launch waves that keep prescribing decisions fluid and competitive. Network meta-analysis highlights batoclimab’s superior QMG response and rozanolixizumab’s leading MG-ADL gains, implying eventual algorithm-based drug selection. Such data-driven personalization supports sustained biologic share expansion inside the myasthenia gravis therapeutics market while giving payers levers to negotiate value-based contracts.

By End-User: Home-Care Settings Capture Fastest Growth

Home-care settings are expanding at a 10.54% CAGR, challenging hospitals that held a 58.88% share in 2025. The COVID-19 experience normalized self-injection and tele-monitoring, reducing patient anxiety about administering high-value biologics at home. AI-enabled platforms now automate neuromuscular examinations, allowing clinicians to adjust dosing based on remote performance scores. Over the forecast horizon, the myasthenia gravis therapeutics market is expected to experience a steady shift in maintenance dosing from specialty clinics to patients' homes.

Hospitals still dominate initiation because neurologists perform baseline assessments, infusion titrations, and crisis management. Ambulatory surgery centers continue to play a role in thymectomy and electrophysiology, yet billing volumes are declining as biologics reduce procedural demand. Payers endorse decentralisation when adherence metrics prove stable, and some insurers offer premium discounts to patients who transition to home administration. This shift reallocates revenue streams but enlarges the overall myasthenia gravis therapeutics market by removing logistical barriers to chronic care.

Geography Analysis

North America generated 44.01% of 2025 revenue, underpinned by broad insurance coverage and rapid biologic uptake following FDA breakthrough designations. Incidence now sits at 68.5 per million, equating to roughly 82,700 U.S. adults needing ongoing therapy. AI-enabled ocular-motor testing and tele-neurology reduce specialist bottlenecks, promoting early starts that heighten cumulative drug exposure. Competitive intensity rose in 2025 when Johnson & Johnson launched nipocalimab, adding price tension that may widen patient access by tempering annual cost escalators.

Europe follows with a cohesive regulatory environment that approved rozanolixizumab in January 2024 and SC self-administration in February 2025. Health-technology assessments secure 20-30% list-price discounts, yet still recognise orphan-drug value where real-world data show faster steroid tapering and fewer crises. Preference studies confirm 83% of European patients favor SC dosing, letting payers reallocate infusion budgets to drug acquisition. Conditional approvals require post-market surveillance, ensuring safety transparency while allowing income flow during data collection. Rising biosimilar programs for complement inhibitors could generate additional savings, potentially funding broader FcRn adoption across national formularies.

Asia-Pacific is the fastest-growing region at a 9.46% CAGR, buoyed by PMDA and NMPA reviews that now lag U.S. clearances by less than six months. Japan approved efgartigimod as VYVDURA for generalized myasthenia gravis and immune thrombocytopenia, while China authorised both IV and SC forms for gMG and CIDP. Despite these gains, out-of-pocket costs still average 40% of annual household income in China, which caps utilisation for high-priced biologics. Telemedicine and AI-based infrared spectroscopy are beginning to close specialist gaps. Continued healthcare-infrastructure investment and local manufacturing initiatives, including planned FcRn biosimilars, should lift the regional contribution to the myasthenia gravis therapeutics market over the next decade.

Regulatory Landscape

Regulatory activity across major markets continues to shape access to gMG therapies through accelerated and harmonized pathways for rare-disease biologics. In the United States, the FDA expanded labeling for FcRn-directed therapy in May 2026 to cover all adult serotypes of generalized MG, broadening eligibility and real-world use.

In Europe and the United Kingdom, multiple anchors anchor the regulatory arc: EMA granted marketing authorization for Imaavy (nipocalimab) in November 2025; the UK MHRA authorized Imaavy for adults and adolescents aged 12 and older in June 2026; and the EMA opened a public consultation on clinical investigation guidelines for myasthenia gravis from 13 February 2026 to 30 August 2026, signaling emphasis on endpoints and trial designs amid rapid pipeline expansion.

Value Chain Analysis

The value chain for myasthenia gravis therapeutics spans discovery and clinical development of targeted immunology assets (FcRn blockers, complement inhibitors, and B-cell directed therapies), biologics manufacturing (drug substance plus aseptic fill-finish), and specialist-led commercialization into neurology channels. As high-cost biologics broaden their labels, regulatory-compliant manufacturing and change control (for example, FDA biologics requirements for facility changes and distribution reporting) remain central to maintaining supply continuity and supporting multi-region submissions.

On the commercialization and distribution side, specialty channels play an outsized role because many therapies require prior authorization, cold-chain handling, and patient support for home or outpatient use. Limited specialty pharmacy networks, such as PANTHERx Rare supporting UCB's Rystiggo, have become critical nodes that coordinate payer access, patient onboarding, and distribution for self-administered products. Manufacturing capacity and technical capabilities are supported through specialized partners, including FUJIFILM Diosynth Biotechnologies in argenx's supply ecosystem and Recipharm collaborations for development and scale-up, aligning the supply chain to rising demand for subcutaneous presentations and broader patient eligibility.

Market Opportunities and Future Outlook

Regulatory actions broaden access to gMG therapies. In the United States, the FDA expanded labeling for FcRn therapies in May 2026 to encompass all adult serotypes of generalized MG, expanding eligible patient populations. In Europe, the EMA granted marketing clearance for Imaavy in November 2025, and the UK MHRA followed with June 2026 approval for adults and adolescents aged 12 and older, establishing differentiated cross-country pathways and cross-recognition arrangements. The EMA also initiated a February 2026 public consultation on revised clinical investigation guidelines for MG, signaling alignment on endpoints and study design amid rapid pipeline growth.

Product differentiation around dosing convenience and administration routes continues to shape therapy choices. Amgen's UPLIZNA moved from the US to EC approval in February 2026 as an add-on option for AChR or MuSK antibody-positive gMG, illustrating cross-market momentum for B-cell targeted approaches alongside FcRn blockers. Separately, Regeneron's cemdisiran has progressed with regulatory submissions accepted by the FDA and EMA in June 2026 for adults with AChR antibody-positive MG, underscoring ongoing exploration of less frequent dosing constructs and potential reductions in site-of-care costs.